Free Trial

Swedish Orphan Biovitrum (BIOVF) Short Interest Ratio & Short Volume

Swedish Orphan Biovitrum logo
$30.75 +1.78 (+6.14%)
As of 08/22/2025 10:26 AM Eastern

Swedish Orphan Biovitrum Short Interest Data

Swedish Orphan Biovitrum (BIOVF) has a short interest of 178,300 shares, representing 0.05% of the float (the number of shares available for trading by the public). This marks a -43.84% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1,783.0, indicating that it would take 1,783.0 days of the average trading volume of 39 shares to cover all short positions.

Current Short Interest
178,300 shares
Previous Short Interest
317,500 shares
Change Vs. Previous Month
-43.84%
Dollar Volume Sold Short
$5.31 million
Short Interest Ratio
1,783.0 Days to Cover
Last Record Date
July 31, 2025
Outstanding Shares
356,000,000 shares
Short Percent of Float
0.05%
Today's Trading Volume
243 shares
Average Trading Volume
39 shares
Today's Volume Vs. Average
629%
Short Selling Swedish Orphan Biovitrum?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Swedish Orphan Biovitrum and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

BIOVF Short Interest Over Time

BIOVF Days to Cover Over Time

BIOVF Percentage of Float Shorted Over Time

Swedish Orphan Biovitrum Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/31/2025178,300 shares $5.31 million -43.8%0.1%1783 $29.79
7/15/2025317,500 shares $9.29 million -60.6%N/A3175 $29.25
6/30/2025805,300 shares $23.56 million -17.7%0.2%4026.5 $29.25
6/15/2025978,400 shares $31.30 million +4.8%0.3%9784 $31.99
5/31/2025933,300 shares $28.27 million +3.0%0.3%1166.6 $30.29
5/15/2025906,600 shares $27.65 million -11.4%0.3%4533 $30.50
4/30/20251,023,100 shares $31.36 million -16.6%N/A10231 $30.66
4/15/20251,227,000 shares $33.01 million +9.6%0.3%1752.9 $26.90
3/31/20251,119,800 shares $32.15 million +43.6%0.3%11198 $28.71
3/15/2025779,800 shares $23.39 million +35.9%0.2%7798 $29.99
2/28/2025573,800 shares $17.04 million +0.3%0.2%5738 $29.70
2/15/2025572,000 shares $17.43 million -11.0%0.2%5720 $30.48
1/31/2025642,400 shares $19.58 million -55.7%N/A6424 $30.48
1/15/20251,450,700 shares $41.05 million +5.3%N/A14507 $28.30
12/31/20241,377,300 shares $38.10 million -7.9%N/A13773 $27.66
12/15/20241,494,600 shares $42.78 million -1.5%N/A7473 $28.62
11/30/20241,517,000 shares $41.31 million -10.2%N/A15170 $27.23
11/15/20241,688,500 shares $52.99 million +90.3%N/A16885 $31.38
10/31/2024887,500 shares $28.41 million -14.6%N/A8875 $32.01
10/15/20241,038,600 shares $30.64 million +33.0%N/A10386 $29.50
9/30/2024780,900 shares $24.45 million -31.5%N/A2603 $31.31
9/15/20241,139,700 shares $35.65 million +3.0%N/A1628.1 $31.28
8/31/20241,107,000 shares $34.63 million -9.6%N/A11070 $31.28
8/15/20241,224,400 shares $29.48 million -4.1%N/A3061 $24.08
7/31/20241,276,900 shares $34.74 million -4.9%N/A1418.8 $27.21
7/15/20241,342,000 shares $35.58 million -5.1%N/A4473.3 $26.51
6/30/20241,414,600 shares $38.13 million -5.1%N/A4715.3 $26.96
6/15/20241,490,900 shares $39.26 million -1.6%N/A3727.2 $26.33
5/31/20241,514,400 shares $39.00 million -4.8%N/A0 $25.76
5/15/20241,591,500 shares $40.99 million +36.9%N/A2273.6 $25.76
4/30/20241,162,200 shares $26.58 million +48.9%N/A1937 $22.87
4/15/2024780,600 shares $19.52 million +6.3%N/A7806 $25.00
3/31/2024734,400 shares $19.79 million +9.8%N/A3672 $26.95
3/15/2024669,100 shares $18.59 million +3.8%N/A6691 $27.79
2/29/2024644,500 shares $15.31 million +18.7%N/A6445 $23.75
2/15/2024543,100 shares $12.67 million +27.6%N/A5431 $23.32
1/15/2024456,200 shares $12.32 million -17.1%N/A1520.7 $27.00
12/31/2023550,100 shares $14.44 million -4.1%N/A2957.4 $26.25
12/15/2023573,800 shares $13.28 million +2.6%N/A2869 $23.15
11/30/2023559,200 shares $11.77 million -1.4%N/A5592 $21.05
Musk’s Project Colossus could mint millionaires (Ad)

I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel

All the details are waiting for you now — but you need to act before the September 1st funding windo
11/15/2023567,000 shares $11.94 million -0.7%N/A2835 $21.05
10/31/2023570,700 shares $11.57 million +8.5%N/A1426.8 $20.27
10/15/2023526,200 shares $10.94 million +15.7%N/A5262 $20.80
9/30/2023454,900 shares $9.46 million +11.3%N/A2274.5 $20.80
9/15/2023408,800 shares $8.16 million +33.9%N/A4088 $19.95
8/31/2023305,200 shares $5.98 million +34.9%N/A953.6 $19.61
8/15/2023226,200 shares $4.38 million +16.8%N/A2262 $19.35
7/31/2023193,700 shares $3.83 million +12.2%N/A1937 $19.75
7/15/2023172,600 shares $3.36 million +0.9%N/A575.3 $19.45
6/30/2023171,100 shares $3.64 million +3.7%N/A1711 $21.25
6/15/2023165,000 shares $3.51 million +23.7%N/A1650 $21.25
5/31/2023133,400 shares $2.66 million +33.4%N/A190.6 $19.92
5/15/2023100,000 shares $2.19 million -66.2%N/A200 $21.89
4/30/2023295,900 shares $7.81 million +0.6%N/A2959 $26.40
4/15/2023294,100 shares $7.79 million -9.7%N/A735.3 $26.48
3/31/2023325,500 shares $7.52 million +1.6%N/A813.8 $23.11
3/15/2023320,400 shares $7.29 million -28.4%N/A3204 $22.74
2/28/2023447,200 shares $10.08 million +41.6%N/A1118 $22.55
2/15/2023315,900 shares $7.49 million +3.9%N/A263.3 $23.70
1/31/2023304,000 shares $6.88 million +31.7%N/A1013.3 $22.63
1/15/2023230,800 shares $5.05 million +6.0%N/A177.5 $21.89
12/30/2022217,700 shares $4.60 million -48.6%N/A1088.5 $21.15
12/15/2022423,200 shares $8.95 million +237.8%N/A4232 $21.15
11/30/2022125,300 shares $2.65 million -72.4%N/A1253 $21.15
11/15/2022454,000 shares $8.80 million +6.3%N/A12 $19.38
10/31/2022427,000 shares $7.79 million +9.6%N/A4270 $18.25
10/15/2022389,600 shares $7.11 million -1.3%N/A354.2 $18.25
9/30/2022394,700 shares $7.33 million -1.9%N/A657.8 $18.58
9/15/2022402,500 shares $8.33 million +4.9%N/A4025 $20.70
8/31/2022383,600 shares $8.67 million +2.4%N/A1918 $22.60
8/15/2022374,700 shares $8.74 million +0.2%N/A3747 $23.33
7/31/2022373,900 shares $7.93 million +16.7%N/A3739 $21.20
7/15/2022320,300 shares $6.79 million -3.2%N/A3203 $21.20
6/30/2022330,900 shares $7.25 million -37.8%N/A1654.5 $21.92
6/15/2022532,100 shares $10.83 million -0.1%N/A5321 $20.36
5/31/2022532,500 shares $11.56 million -37.9%N/A760.7 $21.70
5/15/2022856,900 shares $17.14 million +34.6%N/A4284.5 $20.00
4/30/2022636,600 shares $13.43 million +4.7%N/A3183 $21.10
4/15/2022607,800 shares $14.70 million -3.2%N/A1215.6 $24.18
3/31/2022628,000 shares $14.29 million -2.7%N/A2093.3 $22.75
3/15/2022645,600 shares $12.91 million +13.3%N/A6456 $20.00
2/28/2022569,900 shares $11.65 million -0.6%N/A5699 $20.45
2/15/2022573,200 shares $11.83 million -2.3%N/A1433 $20.64
1/31/2022586,800 shares $11.15 million +818.3%N/A5868 $19.00
1/15/202263,900 shares $1.30 million -14.2%N/A319.5 $20.30
12/31/202174,500 shares $1.52 million +4.5%N/A248.3 $20.39
12/15/202171,300 shares $1.41 million -87.7%N/A44.6 $19.76
11/30/2021581,600 shares $14.53 million +500.8%N/A5816 $24.99
11/15/202196,800 shares $2.54 million -8.0%N/A322.7 $26.25
10/29/2021105,200 shares $2.82 million +3.8%N/A116.9 $26.81
Musk’s Project Colossus could mint millionaires (Ad)

I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel

All the details are waiting for you now — but you need to act before the September 1st funding windo
10/15/2021101,400 shares $2.75 million -75.3%N/A26.7 $27.13
9/30/2021410,200 shares $11.21 million -17.5%N/A141.4 $27.33
9/15/2021497,100 shares $13.95 million +10.5%N/A113 $28.06
8/31/2021449,900 shares $9.90 million -40.3%N/A86.5 $22.00
8/13/2021753,300 shares $14.52 million -23.7%N/A2511 $19.28
7/30/2021987,500 shares $19.83 million -0.1%N/A548.6 $20.08
7/15/2021988,900 shares $18.79 million -8.6%N/A9889 $19.00
6/30/20211,081,900 shares $19.67 million +3.4%N/A3606.3 $18.18
6/15/20211,046,200 shares $20.77 million -5.8%N/A317 $19.85
5/28/20211,110,500 shares $17.82 million -0.5%N/A1586.4 $16.05
5/14/20211,115,800 shares $18.41 million -42.1%N/A5579 $16.50
4/30/20211,925,300 shares $33.31 million +0.2%N/A3850.6 $17.30
4/15/20211,920,600 shares $32.56 million +37.8%N/A19206 $16.96
3/31/20211,394,000 shares $21.61 million +5.4%N/A2323.3 $15.50
3/15/20211,322,600 shares $23.03 million -2.2%N/A2204.3 $17.41
2/26/20211,352,200 shares $22.58 million +44.1%N/A1502.4 $16.70
2/12/2021938,500 shares $18.77 million +17.5%N/A1877 $20.00
1/29/2021798,700 shares $14.91 million +34.6%N/A998.4 $18.67
1/15/2021570,400 shares $11.34 million +4.1%N/A1426 $19.88
12/31/2020618,300 shares $12.09 million +8.4%N/A6183 $19.55
12/15/2020570,400 shares $11.30 million +4.1%N/A1426 $19.81
11/30/2020548,000 shares $9.78 million -18.3%N/A548 $17.85
11/15/2020670,700 shares $12.37 million +4.5%N/A958.1 $18.44
10/30/2020642,100 shares $10.77 million -27.4%N/A237.8 $16.77
10/15/2020884,000 shares $18.21 million +120.8%N/A1473.3 $20.60
9/30/2020400,300 shares $9.71 million -62.7%N/A400.3 $24.25
9/15/20201,074,400 shares $26.59 million +5.6%N/A2686 $24.75
8/31/20201,017,800 shares $22.70 million +1.7%N/A1272.3 $22.30

BIOVF Short Interest - Frequently Asked Questions

What is Swedish Orphan Biovitrum's current short interest?

Short interest is the volume of Swedish Orphan Biovitrum shares that have been sold short but have not yet been covered or closed out. As of July 31st, investors have sold 178,300 shares of BIOVF short. 0.05% of Swedish Orphan Biovitrum's shares are currently sold short. Learn More on Swedish Orphan Biovitrum's current short interest.

What is a good short interest ratio for Swedish Orphan Biovitrum?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BIOVF shares currently have a short interest ratio of 1,783.0. Learn More on Swedish Orphan Biovitrum's short interest ratio.

What is a good short interest percentage for Swedish Orphan Biovitrum?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.05% of Swedish Orphan Biovitrum's floating shares are currently sold short.

Is Swedish Orphan Biovitrum's short interest increasing or decreasing?

Swedish Orphan Biovitrum saw a drop in short interest in July. As of July 31st, there was short interest totaling 178,300 shares, a drop of 43.8% from the previous total of 317,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Swedish Orphan Biovitrum's short interest compare to its competitors?

0.05% of Swedish Orphan Biovitrum's shares are currently sold short. Here is how the short interest of companies in the industry of "med - biomed/gene" compare to Swedish Orphan Biovitrum: argenex SE (3.15%), Insmed, Inc. (4.65%), BioNTech SE Sponsored ADR (2.56%), Royalty Pharma PLC (4.57%), Biogen Inc. (2.71%), Sino Biopharmaceutical (0.08%), Incyte Corporation (3.85%), Genmab A/S (0.05%), Illumina, Inc. (5.16%), Genmab A/S Sponsored ADR (0.58%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks.

What does it mean to sell short Swedish Orphan Biovitrum stock?

Short selling BIOVF is an investing strategy that aims to generate trading profit from Swedish Orphan Biovitrum as its price is falling. BIOVF shares are trading up $1.78 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Swedish Orphan Biovitrum?

A short squeeze for Swedish Orphan Biovitrum occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BIOVF, which in turn drives the price of the stock up even further.

How often is Swedish Orphan Biovitrum's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BIOVF, twice per month. The most recent reporting period available is July, 31 2025.




This page (OTCMKTS:BIOVF) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners